Open Nav

OncoTAb, Inc.

  • Rahul Puri, OncoTAb, Inc.

Seeking Series A funding & strategic partner

  • Date:Wednesday, October 17
  • Time:11:15 AM - 11:30 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:OncoTAb’s vision is to develop and commercialize a continuum of products to address unmet needs in breast and pancreatic cancer diagnosis and treatment. The technology platform on which these products are being developed is a patented monoclonal antibody (TAB004) that specifically recognizes the tumor form of MUC1 (tMUC1) on breast cancer cells and does not recognize normal MUC1/breast epithelia. Fully humanized TAB004 (hTAB004) has been used to demonstrate imaging breast and pancreatic cancer in-vivo, with localization of hTAB004 on tumors but not on healthy tissue. The company successfully demonstrated exquisite targeting of triple negative breast cancer (TNBC) xenograft tumors with Actinium-225 labeled hTAB004 under a Phase 1 contract award from the NCI. The treated animals showed 90% regression of tumors and 100% survival. hTAB004 is a strong candidate for ADC's targeting TNBC and pancreatic cancers. OncoTAb is seeking a strategic partnership to develop hTAB004 for therapy.
  • Company
  • Company HQ City:Charlotte
  • Company HQ Country:United States
  • Company HQ State:North Carolina       
  • CEO/Top Company Official:Rahul Puri
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Targeted Radiotherapy for Triple Negative Breast Cancer
  • Development Phase of Primary Product:Pre-Clinical
  • Previous and Current Investors:Angels, Inception Micro Angel Fund, NCI
  • Total Amount Raised to Date, In All Rounds:$3,000,000
Rahul Puri
OncoTAb, Inc.